DPZ Down 3.5% and JNJ Down 5%: Earnings Season's Early Losers

Earnings season has a way of sorting winners from pretenders fast, and this week it handed out two very public beatdowns. $DPZ dropped roughly 3.5% after same-store sales grew less than expected, and $JNJ is on track for its worst single-day drop since April 2025, falling more than 5% on a MedTech miss that Wall Street is not letting slide.

Start with Domino's, because this one stings. The company launched a new personal-sized pizza at a discount price, hoping to drive traffic in one of the most brutally competitive fast-food price wars in recent memory. It didn't work. According to Bloomberg's Stock Movers coverage, the item failed to drive meaningful same-store sales growth. When your promotional pizza isn't moving the needle, that's a problem, not a menu update. The stock was already fighting the macro: small business optimism just dropped to 97.9 on the NFIB index (down 0.8 points), and 31% of small business owners raised prices in September. Consumers are tired.

Johnson and Johnson is a stranger story. The pharma unit is genuinely exceptional: oncology and neuroscience each grew 17%, and immunology returned to growth despite a $900 million Stelara headwind. CFO Joseph Wolk basically said you can't praise the pharma division enough, and he's not wrong. But MedTech grew only 2.5%, partly blamed on Middle East conflict disruptions. The company is now leaning toward spinning off its orthopedics unit rather than selling it, which collapsed what was reportedly a $20 billion Apollo deal. Investors were pricing in that deal. They weren't pricing in a spin-off. Hence the face-plant.

YouTube's financial channels are treating these two very differently. Bloomberg Podcasts is covering JNJ's drop with genuine nuance, pointing out the profit guidance raise as a reason not to panic. The pharma story is real. The MedTech drag looks temporary, especially with the heart recovery segment expected to catalyze double-digit growth next year. On Domino's, the tone is colder: nobody seems surprised, and nobody is rushing to buy the dip.

The broader market backdrop doesn't help either name. The Nasdaq closed down 0.44% on Monday, chip stocks are sliding, and Paul Tudor Jones is out here comparing the market to 1999 on CNBC. Consumer discretionary and defensive healthcare both have headwinds right now. If you're going to miss, this is the worst week to do it.

JNJ has a real pharma engine that could carry the stock back. Domino's needs more than a personal pizza to fix a same-store sales problem in an economy where the consumer is quietly exhausted.